Mirvetuximab

Mirvetuximab represents a novel category of cancer therapy recognized as an antibody-drug conjugate. Its mode of action revolves around targeting folate receptor alpha (FRα), a protein notably abundant on the surface of various cancer cells, notably ovarian cancer cells. Upon binding to FRα, Mirvetuximab infiltrates the cancer cell, releasing a potent chemotherapy drug directly into its core. Subsequently, the administered drug induces cell death within the cancerous cells. This precise mechanism enables the delivery of concentrated chemotherapy doses specifically to cancer cells, thereby mitigating harm to healthy cells.